DeCure for Ehlers-Danlos syndrome, spondylodysplastic type
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Ehlers-Danlos syndrome, spondylodysplastic type — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEhlers-Danlos syndrome, spondylodysplastic type maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ehlers-danlos syndrome, spondylodysplastic type is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
beta-1,4-galactosyltransferase 7 (B4GALT7) — B4GALT7 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet udpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4IRP · 2.1 Å · ligand URIDINE-5'-DIPHOSPHATE (UDP). Experimental structure, not a prediction.
What the evidence adds up to
The three abstracts cover orthopaedic management, vascular complications, and a single chronic pain case, but none report a drug trial or any pharmacological intervention for Ehlers-Danlos syndrome, spondylodysplastic type. The 2017 review states that non-operative treatment is preferable for EDS generally and that joint stabilisation and nerve decompression can provide symptomatic relief in carefully selected patients when conservative measures fail; no drug is mentioned. The 1982 paper describes EDS as a heterogeneous disorder of connective tissue synthesis and notes that most patients with major vascular complications lack the usual musculoskeletal and cutaneous signs; it suggests that applying accepted vascular surgical techniques may improve morbidity and mortality, but again no drug is discussed. The 2021 case report describes a 17-year-old male with hypermobility-type EDS (not spondylodysplastic) who presented with widespread pain for four years; the report concludes only that the diagnosis was made using Brighton criteria and does not describe any treatment, drug or otherwise.
No abstract in this set provides any data on drug repurposing, response rates, survival, or sample sizes for any medication in Ehlers-Danlos syndrome, spondylodysplastic type. The spondylodysplastic subtype is not mentioned in any of the three abstracts. There is no evidence here for or against any drug’s efficacy in this condition.
What is missing is any clinical trial, any pharmacological study, any patient stratification by molecular subtype, and any funding directed at drug repurposing for spondylodysplastic EDS. Without such studies, no conclusion about drug treatment can be drawn.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part C Seminars in Medical Genetics · 2017 · 93 citations
Orthopaedic management of the Ehlers–Danlos syndromes
Vascular Manifestations in Patients With Ehlers-Danlos Syndrome
AbstractEhlers-Danlos syndrome (EDS) is clinically and genetically a heterogenous disorder of connective tissue synthesis. Seven clinical types of this disease have been identified and the underlying biochemical defects defined in types IV through VII. Unfortunately, most patients with major vascular complications of EDS have few, if any of the commonly recognized musculoskeletal and cutaneous abnormalities. Recognition of the correct diagnosis and the application of accepted vascular surgical techniques may improve the morbidity and mortality for these patients.
Ehlers-Danlos syndrome in chronic pain patient. Case report
AbstractABSTRACT BACKGROUND AND OBJECTIVES: Ehlers-Danlos Syndrome is a connective tissue disease which becomes disabling in some cases. This study aimed at presenting a rare case diagnosed in the Ambulatory of Symptoms Control and Palliative Care with severe pain. CASE REPORT: Male patient, 17 years old, who came to the ambulatory complaining of widespread pain for 4 years. He referred history of joint hypermobility noticed since childhood. CONCLUSION: Based on clinical history and physical evaluation, in addition to Brighton criteria, patient was diagnosed as having hypermobility-type Ehlers-Danlos Syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
